Cargando…
Structure-based assessment and druggability classification of protein–protein interaction sites
The featureless interface formed by protein–protein interactions (PPIs) is notorious for being considered a difficult and poorly druggable target. However, recent advances have shown PPIs to be druggable, with the discovery of potent inhibitors and stabilizers, some of which are currently being clin...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106675/ https://www.ncbi.nlm.nih.gov/pubmed/35562538 http://dx.doi.org/10.1038/s41598-022-12105-8 |
_version_ | 1784708344856969216 |
---|---|
author | Alzyoud, Lara Bryce, Richard A. Al Sorkhy, Mohammad Atatreh, Noor Ghattas, Mohammad A. |
author_facet | Alzyoud, Lara Bryce, Richard A. Al Sorkhy, Mohammad Atatreh, Noor Ghattas, Mohammad A. |
author_sort | Alzyoud, Lara |
collection | PubMed |
description | The featureless interface formed by protein–protein interactions (PPIs) is notorious for being considered a difficult and poorly druggable target. However, recent advances have shown PPIs to be druggable, with the discovery of potent inhibitors and stabilizers, some of which are currently being clinically tested and approved for medical use. In this study, we assess the druggability of 12 commonly targeted PPIs using the computational tool, SiteMap. After evaluating 320 crystal structures, we find that the PPI binding sites have a wide range of druggability scores. This can be attributed to the unique structural and physiochemical features that influence their ligand binding and concomitantly, their druggability predictions. We then use these features to propose a specific classification system suitable for assessing PPI targets based on their druggability scores and measured binding-affinity. Interestingly, this system was able to distinguish between different PPIs and correctly categorize them into four classes (i.e. very druggable, druggable, moderately druggable, and difficult). We also studied the effects of protein flexibility on the computed druggability scores and found that protein conformational changes accompanying ligand binding in ligand-bound structures result in higher protein druggability scores due to more favorable structural features. Finally, the drug-likeness of many published PPI inhibitors was studied where it was found that the vast majority of the 221 ligands considered here, including orally tested/marketed drugs, violate the currently acceptable limits of compound size and hydrophobicity parameters. This outcome, combined with the lack of correlation observed between druggability and drug-likeness, reinforces the need to redefine drug-likeness for PPI drugs. This work proposes a PPI-specific classification scheme that will assist researchers in assessing the druggability and identifying inhibitors of the PPI interface. |
format | Online Article Text |
id | pubmed-9106675 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-91066752022-05-15 Structure-based assessment and druggability classification of protein–protein interaction sites Alzyoud, Lara Bryce, Richard A. Al Sorkhy, Mohammad Atatreh, Noor Ghattas, Mohammad A. Sci Rep Article The featureless interface formed by protein–protein interactions (PPIs) is notorious for being considered a difficult and poorly druggable target. However, recent advances have shown PPIs to be druggable, with the discovery of potent inhibitors and stabilizers, some of which are currently being clinically tested and approved for medical use. In this study, we assess the druggability of 12 commonly targeted PPIs using the computational tool, SiteMap. After evaluating 320 crystal structures, we find that the PPI binding sites have a wide range of druggability scores. This can be attributed to the unique structural and physiochemical features that influence their ligand binding and concomitantly, their druggability predictions. We then use these features to propose a specific classification system suitable for assessing PPI targets based on their druggability scores and measured binding-affinity. Interestingly, this system was able to distinguish between different PPIs and correctly categorize them into four classes (i.e. very druggable, druggable, moderately druggable, and difficult). We also studied the effects of protein flexibility on the computed druggability scores and found that protein conformational changes accompanying ligand binding in ligand-bound structures result in higher protein druggability scores due to more favorable structural features. Finally, the drug-likeness of many published PPI inhibitors was studied where it was found that the vast majority of the 221 ligands considered here, including orally tested/marketed drugs, violate the currently acceptable limits of compound size and hydrophobicity parameters. This outcome, combined with the lack of correlation observed between druggability and drug-likeness, reinforces the need to redefine drug-likeness for PPI drugs. This work proposes a PPI-specific classification scheme that will assist researchers in assessing the druggability and identifying inhibitors of the PPI interface. Nature Publishing Group UK 2022-05-13 /pmc/articles/PMC9106675/ /pubmed/35562538 http://dx.doi.org/10.1038/s41598-022-12105-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Alzyoud, Lara Bryce, Richard A. Al Sorkhy, Mohammad Atatreh, Noor Ghattas, Mohammad A. Structure-based assessment and druggability classification of protein–protein interaction sites |
title | Structure-based assessment and druggability classification of protein–protein interaction sites |
title_full | Structure-based assessment and druggability classification of protein–protein interaction sites |
title_fullStr | Structure-based assessment and druggability classification of protein–protein interaction sites |
title_full_unstemmed | Structure-based assessment and druggability classification of protein–protein interaction sites |
title_short | Structure-based assessment and druggability classification of protein–protein interaction sites |
title_sort | structure-based assessment and druggability classification of protein–protein interaction sites |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106675/ https://www.ncbi.nlm.nih.gov/pubmed/35562538 http://dx.doi.org/10.1038/s41598-022-12105-8 |
work_keys_str_mv | AT alzyoudlara structurebasedassessmentanddruggabilityclassificationofproteinproteininteractionsites AT brycericharda structurebasedassessmentanddruggabilityclassificationofproteinproteininteractionsites AT alsorkhymohammad structurebasedassessmentanddruggabilityclassificationofproteinproteininteractionsites AT atatrehnoor structurebasedassessmentanddruggabilityclassificationofproteinproteininteractionsites AT ghattasmohammada structurebasedassessmentanddruggabilityclassificationofproteinproteininteractionsites |